Encouraging Physician Adoption of Genetic Testing for Precision Medicine

Delaney, Susan; Christman, Michael F.

doi:10.2217/pme-2016-0005

Cited by 3 publications

(2 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The benefits of blockchain extend beyond eliminating intermediaries and increasing transparency; they also encompass enhanced security, fraud reduction, and improved targeting in digital advertising. This paper will dive deeper into the potential applications of blockchain in marketing, exploring case studies, challenges, and future prospects for this groundbreaking technology [21][22][23].…”

Section: A Blockchain Revolutionizing Marketingmentioning

confidence: 99%

Blockchain Revolutionizing Marketing: Harnessing the Power of Distributed Ledgers for Transparent, Secure, and Efficient Marketing Practices

Rathore¹

2019

IJNMS

View full text Add to dashboard Cite

This study explores the transformative potential of blockchain technology in revolutionizing marketing practices. With the rise of digital marketing and concerns about privacy, transparency, and efficiency, blockchain offers solutions to these challenges. By leveraging the decentralized and immutable nature of distributed ledgers, marketers can establish trust, enhance security, and foster transparency throughout the advertising supply chain. This research examines various applications of blockchain in marketing, such as verifying ad impressions, combating ad fraud, ensuring data integrity, and optimizing customer reward programs. Through these use cases, blockchain demonstrates its ability to reshape marketing, paving the way for a more accountable, secure, and efficient future.

show abstract

Section: A Blockchain Revolutionizing Marketingmentioning

confidence: 99%

Blockchain Revolutionizing Marketing: Harnessing the Power of Distributed Ledgers for Transparent, Secure, and Efficient Marketing Practices

Rathore¹

2019

IJNMS

View full text Add to dashboard Cite

show abstract

“…As research shows, even though there is compelling evidence of the benefits of new technologies, such as these tests, their use in clinical practice can be hampered by a dynamic interplay of factors at the individual level and at the level of the broader, organizational context [4][5][6]. Healthcare providers might be hesitant about using biomarker tests, for instance, because they do not want to change their professional routines or because they are not fully aware of or lack knowledge about molecular biomarkers [7][8][9]. Previous studies on a molecular biomarker test for breast cancer, for example, showed that the level of use of this test varied among oncologists [10,11].…”

mentioning

confidence: 99%

The Use of Molecular Biomarker Tests: An Interview Study with Healthcare Providers about a Molecular Biomarker Test for Prostate Cancer

Wendrich

Krabbenborg

2021

Per. Med.

View full text Add to dashboard Cite

Aim: Investigate why healthcare providers are not always willing to use molecular biomarker tests, even though they promise to personalize disease diagnosis and treatment. Materials & methods: We interviewed 20 Dutch urological healthcare providers to ascertain why they used or did not use SelectMDx, a biomarker test for prostate cancer. Results: Whether and how it was used differed from the developers’ expectations, because users and nonusers disagreed about its perceived advantages; the scientific and clinical evidence; the advantages of MRI; and the value of PCA3 testing. Financial issues and the absence of SelectMDx in professional guidelines and hospital care pathways also hampered its use. Conclusion: Eliciting users’ and nonusers’ views is important to better understand how biomarker tests can be embedded in clinical practice.

show abstract